Collaud Stéphane, Bongiovanni Massimo, Pache Jean-Claude, Fioretta Gérald, Robert John H
Service of Thoracic Surgery, Geneva University Hospital, Geneva, Switzerland.
J Thorac Cardiovasc Surg. 2009 Mar;137(3):622-6. doi: 10.1016/j.jtcvs.2008.10.017.
We performed a retrospective study evaluating the effect on survival of different sites of microscopic residual disease at the bronchial resection margin after surgical intervention for non-small cell lung cancer.
Survival of patients with different sites of residual disease was compared with survival of patients with curative resections, taking the pathologic TNM stage of the tumor into consideration.
There was a trend for patients with stage I and II non-small cell lung cancer with residual disease limited to the epithelium and with peribronchial invasion to behave like patients with complete resections (61% and 41% five-year survival for stage I and II disease, respectively). This contrasts with patients with submucosal invasion and lymphatic infiltration, among whom there were no survivors at 5 years. There was no difference in survival between curative resections and residual disease of any type when the tumor was stage III or IV.
In patients with stage I and II disease, when residual disease consists of submucosal invasion or lymphatic infiltration, specific and aggressive treatments to clear residual margins might be contemplated because of their possible adverse effect on survival. This contrasts with patients with stage III and IV disease, in whom survival is more related to the stage of the primary tumor than to residual disease.
我们进行了一项回顾性研究,评估非小细胞肺癌手术干预后支气管切除边缘不同部位微小残留病灶对生存的影响。
将不同部位残留病灶患者的生存率与根治性切除患者的生存率进行比较,同时考虑肿瘤的病理TNM分期。
I期和II期非小细胞肺癌且残留病灶局限于上皮层及有支气管周围浸润的患者,其生存趋势与根治性切除患者相似(I期和II期疾病的五年生存率分别为61%和41%)。这与有黏膜下浸润和淋巴浸润的患者形成对比,后者5年无幸存者。当肿瘤为III期或IV期时,根治性切除与任何类型的残留病灶患者的生存率无差异。
对于I期和II期疾病患者,当残留病灶包括黏膜下浸润或淋巴浸润时,鉴于其可能对生存产生的不利影响,可能需要考虑采取特定的积极治疗以清除残留边缘。这与III期和IV期疾病患者不同,后者的生存更多地与原发肿瘤分期相关,而非残留病灶。